CN101068536B - S1p受体激动剂的剂量方案 - Google Patents

S1p受体激动剂的剂量方案 Download PDF

Info

Publication number
CN101068536B
CN101068536B CN2005800409686A CN200580040968A CN101068536B CN 101068536 B CN101068536 B CN 101068536B CN 2005800409686 A CN2005800409686 A CN 2005800409686A CN 200580040968 A CN200580040968 A CN 200580040968A CN 101068536 B CN101068536 B CN 101068536B
Authority
CN
China
Prior art keywords
alkyl
agonist
substituted
group
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800409686A
Other languages
English (en)
Chinese (zh)
Other versions
CN101068536A (zh
Inventor
J·M·科瓦里克
S·阿佩尔-丁厄曼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101068536(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101068536A publication Critical patent/CN101068536A/zh
Application granted granted Critical
Publication of CN101068536B publication Critical patent/CN101068536B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
CN2005800409686A 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案 Expired - Fee Related CN101068536B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
US60/631,483 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100846463A Division CN102600472A (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案

Publications (2)

Publication Number Publication Date
CN101068536A CN101068536A (zh) 2007-11-07
CN101068536B true CN101068536B (zh) 2012-12-05

Family

ID=36046868

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800409686A Expired - Fee Related CN101068536B (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案
CN2012100846463A Pending CN102600472A (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100846463A Pending CN102600472A (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案

Country Status (21)

Country Link
US (3) US20090275553A1 (enExample)
EP (3) EP2359821A1 (enExample)
JP (4) JP2008521827A (enExample)
KR (4) KR20130041385A (enExample)
CN (2) CN101068536B (enExample)
AU (1) AU2005309378B2 (enExample)
BR (1) BRPI0518674A2 (enExample)
CA (1) CA2589265A1 (enExample)
ES (1) ES2495690T3 (enExample)
IL (2) IL183134A0 (enExample)
MA (1) MA29034B1 (enExample)
MX (1) MX2007006373A (enExample)
NO (2) NO20072401L (enExample)
NZ (2) NZ590054A (enExample)
PL (1) PL1819326T3 (enExample)
PT (1) PT1819326E (enExample)
RU (2) RU2478384C2 (enExample)
SG (2) SG158096A1 (enExample)
TN (1) TNSN07209A1 (enExample)
WO (1) WO2006058316A1 (enExample)
ZA (1) ZA200703328B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509931A (ja) 2004-08-13 2008-04-03 プレーシス ファーマスーティカルズ インコーポレイテッド スフィンゴシン−１−ホスフェート（ｓ１ｐ）レセプター活性を調節するための方法および組成物
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
CA2620554C (en) * 2005-09-09 2013-12-17 Novartis Ag Treatment of autoimmune diseases
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR101526835B1 (ko) 2007-05-04 2015-06-05 노파르티스 아게 Ｓ1ｐ 수용체 조절제의 용도
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
RU2505288C2 (ru) * 2008-05-20 2014-01-27 Киорин Фармасьютикал Ко., Лтд. Средства поддержания индуцированной ремиссии
US9149459B2 (en) * 2008-07-23 2015-10-06 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
RU2523281C2 (ru) * 2008-08-18 2014-07-20 Новартис Аг Соединения для лечения периферических невропатий
CN103204794A (zh) * 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
RU2011129230A (ru) * 2008-12-18 2013-01-27 Новартис Аг Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
HRP20151190T1 (hr) * 2008-12-22 2016-01-01 Novartis Ag Režim doziranja za fingolimod u lijeäśenju multiple skleroze
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
US20120264719A1 (en) * 2009-09-29 2012-10-18 Craig Boulton Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
SI2885266T1 (sl) 2012-08-17 2020-10-30 Actelion Pharmaceuticals Ltd Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2016091996A1 (en) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003099A1 (en) * 2001-06-08 2003-01-02 Philip Lake Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
WO1996006068A1 (en) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
CA2213989C (en) * 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
IL155065A (en) 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1377593B1 (en) 2001-03-26 2005-12-28 Novartis AG 2-amino-propanol derivatives
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
ES2364816T3 (es) * 2001-04-02 2011-09-14 Genentech, Inc. Terapia de combinación.
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
TWI335311B (en) * 2002-09-24 2011-01-01 Novartis Ag Organic compounds
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003099A1 (en) * 2001-06-08 2003-01-02 Philip Lake Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
CN1524002A (zh) * 2001-06-08 2004-08-25 ��˹��ŵ�� 治疗或预防产胰岛素细胞的移植排斥反应
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Andrej Skerjanec et al.Systemic exposure and preliminary effeccacy of FTY720 in denovo renal transplant recipents.Am. J. Transplant2.2002,2380. *

Also Published As

Publication number Publication date
CN102600472A (zh) 2012-07-25
TNSN07209A1 (en) 2008-11-21
KR20140095109A (ko) 2014-07-31
MX2007006373A (es) 2007-06-20
ES2495690T3 (es) 2014-09-17
IL223502A0 (en) 2013-02-03
KR20130041385A (ko) 2013-04-24
US20150087720A1 (en) 2015-03-26
CN101068536A (zh) 2007-11-07
CA2589265A1 (en) 2006-06-01
RU2478384C2 (ru) 2013-04-10
NZ590054A (en) 2012-07-27
SG187468A1 (en) 2013-02-28
KR20150028858A (ko) 2015-03-16
IL183134A0 (en) 2008-04-13
AU2005309378A1 (en) 2006-06-01
HK1109057A1 (en) 2008-05-30
PT1819326E (pt) 2014-09-25
RU2012141951A (ru) 2014-04-10
BRPI0518674A2 (pt) 2008-12-02
JP2013129664A (ja) 2013-07-04
NO20121305L (no) 2007-06-22
SG158096A1 (en) 2010-01-29
NO20072401L (no) 2007-06-22
PL1819326T3 (pl) 2014-12-31
MA29034B1 (fr) 2007-11-01
JP2015061883A (ja) 2015-04-02
US20120071446A1 (en) 2012-03-22
US20090275553A1 (en) 2009-11-05
RU2007124327A (ru) 2009-01-10
WO2006058316A1 (en) 2006-06-01
NZ554720A (en) 2011-04-29
AU2005309378B2 (en) 2010-02-11
EP2359821A1 (en) 2011-08-24
JP2008521827A (ja) 2008-06-26
EP1819326B1 (en) 2014-07-02
KR20070085465A (ko) 2007-08-27
ZA200703328B (en) 2008-08-27
EP2384749A1 (en) 2011-11-09
JP2012107059A (ja) 2012-06-07
EP1819326A1 (en) 2007-08-22

Similar Documents

Publication Publication Date Title
CN101068536B (zh) S1p受体激动剂的剂量方案
DE60103556T2 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten
DE60200492T2 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
JP6624616B2 (ja) ｓＧＣ刺激剤
CN101237852A (zh) 液体制剂
CN101791406B (zh) 1-磷酸-鞘氨醇(s1p)受体激动剂用于制备治疗脑变性性疾病的药物的应用
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
KR20180022661A (ko) 신경퇴행성 질환을 치료하는 방법
CN1406128A (zh) 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用
EA032028B1 (ru) СТИМУЛЯТОРЫ рГЦ
JP2010510214A (ja) Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法
WO2006022428A1 (ja) 糖尿病治療剤
RU2006135927A (ru) Бифенильные соединения, полезные в качестве антагонистов мускариновых рецепторов
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
KR20190094167A (ko) sGC 자극제를 사용한 CNS 질환의 치료
CN101466365A (zh) 增强认知功能的方法
KR20060017763A (ko) 치료에 사용하는 아제티딘카르복스아미드 유도체의 용도
JP2008514718A (ja) 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
RU2007128085A (ru) Соли четвертичного аммония в качестве антагонистов м3
WO1994025023A9 (en) Use of indole derivatives as 5ht1 antagonists
US20210338642A1 (en) Compositions and methods for the treatment or prevention of pulmonary hypertension
EP0808166A1 (fr) Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports
DE69911373T2 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
KR20010013387A (ko) 통증을 치료하기 위한 드라플라진-유사체의 용도
US6492387B2 (en) Isoindolyl and isoquinolinyl aroyl pyrrole compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121205

Termination date: 20141128

EXPY Termination of patent right or utility model